Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs JD.Com Inc (JD) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
JD.Com IncTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs JD.Com Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while JD.Com Inc trades at $31.36 (market cap $44.04B). The key difference: JD.Com Inc is far larger — about 4.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and JD.Com Inc pays a 3.13% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOJD
Market Cap
$9.43B$44.04B
Sector
HealthConsumer Cyclical
52-Week High
$356.25$36.17
52-Week Low
$241.71$25.19
Enterprise Value
$9.18B$30.10B
Dividend Yield
3.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

No Aura AI signal available yet.

JD.Com Inc

JD.com trades at $33.47, up 1.52% today, with a bullish technical setup as price consolidates near recent highs. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue reached $1.31 trillion in 2025. Analyst consensus remains strongly positive with a $38.00 price target, though regulatory scrutiny from EU authorities over the Ceconomy acquisition presents a near-term headwind.

JD offers attractive valuation with a P/S of 0.24 and consistent earnings beats, but faces margin pressure and regulatory risks. Upside potential exists if Q2 2026 results meet high expectations, but investors must weigh competitive pressures in e-commerce and macroeconomic challenges affecting Chinese equities.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About JD.Com Inc

JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Read more on JD